Anti-TANK Antibody

TANK was initially identified as a novel TRAF-interacting protein that regulated TRAF-mediated signal transduction. Specifically, ligand binding by surface receptors in the tumor necrosis factor (TNF) receptor and Toll/interleukin-1 (IL-1) receptor families lead to the formation of a TRAF/TANK complex that mediates the activation of the transcription factor NF-κB. This activation of NF-κB occurs through an association with the kinases IKKε and TBK1. More recently, it was shown that these proteins can then form a complex with NEMO, a protein that regulates the activity of the IκB complex. This suggests that in addition to the possibility that TBK1 and IKKε activate the IKKs, the association with the IKK complex may help these kinases modulate other functions, such as the transactivation potential of NF-κB proteins. At least two isoforms of TANK are known to exist.

TANK antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human TANK. The immunogen is located within amino acids 350 - 400 of TANK.

Adapter protein involved in I-kappa-B-kinase (IKK) regulation which constitutively binds TBK1 and IKBKE playing a role in antiviral innate immunity. Acts as a regulator of TRAF function by maintaining them in a latent state. Blocks TRAF2 binding to LMP1 and inhibits LMP1-mediated NF-kappa-B activation. Negatively regulates NF-kappaB signaling and cell survival upon DNA damage (PubMed:25861989) . Plays a role as an adapter to assemble ZC3H12A, USP10 in a deubiquitination complex which plays a negative feedback response to attenuate NF-kappaB activation through the deubiquitination of IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage (PubMed:25861989) . Promotes UBP10-induced deubiquitination of TRAF6 in response to DNA damage (PubMed:25861989) . May control negatively TRAF2-mediated NF-kappa-B activation signaled by CD40, TNFR1 and TNFR2.

TANK antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.